First in class, best in class or a wild card: who will dominate the anti-obesity medication market?

J Comp Eff Res. 2024 Jul;13(7):e240044. doi: 10.57264/cer-2024-0044. Epub 2024 May 29.
No abstract available

Keywords: AOM; AOM market; GLP-1 agonist; anti-obesity; anti-obesity medication; best-in-class; first-in-class; market access; weight loss.

Publication types

  • Editorial

MeSH terms

  • Anti-Obesity Agents* / economics
  • Anti-Obesity Agents* / therapeutic use
  • Drug Industry / economics
  • Humans
  • Obesity* / drug therapy
  • United States

Substances

  • Anti-Obesity Agents